Vasogen-- VAS on TSE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pluvia who wrote (328)	8/3/2005 9:32:51 PM
From: Clarksterh	Read Replies (1) of 377

"the mortality rate is higher than observed (18.9% at 6.5 months) in some recent HF trials..." The fact that the event rate in placebo group was too high (and I agree that it was - see Yahoo posts long before today) is different than saying that they weren't stat sig. Which is why I pointed out the number of pt's in this trial were too small to produce statistical relevance for mortality. A point anyone who conducts research understands clearly. The p value for a trial already takes into account the size of the trial. By definition. So this is not true. What might be true is that they didn't have enough centers and so center bias crept in. E.g. Only two centers, both of whom provide poor SoC or enrollment bias. But not repeatable in a larger trial with more centers. (I know, I am being a little pedantic here since normally the two (small patient trial population and small number of centers) go together - but not always. In fact the FDA guidelines do not specify trial size, only that it be multicenter.) Clark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next